In 1990, the FTC charged that the test was not valid for this purpose. The company also agreed to pay $30,000 to the National Institutes of Health to support research on yeast infections [11].

This action and several others drove many of the “anti-Candida” concoctions from the marketplace and reduced their direct promotion to the public. However, the ingredients of these products are still marketed individually as “dietary supplements” and practitioners still prescribe them to their patients.

In 1990, the New Jersey State Attorney General secured consent agreements barring Linda Choi, M.D., and Pruyakant Doshi, M.D., from diagnosing and treating “Candida albicans overgrowth syndrome.” Both were assessed $3,000 for investigative costs and had their medical license placed on probation for one year. Among other things, investigation by the State medical board had concluded that “Candida albicans overgrowth” was not generally recognized as a clinical entity and had not been established as the cause of the conditions the doctors treated [12].